In a nutshell This study examined the effectiveness and risks of polyethylene glycol loxenatide (PEX168) as an add-on to metformin (Glucophage) therapy in patients with type 2 diabetes (T2D). It found that PEX168 is safe and works effectively in improving the blood sugar levels in these patients. Some background T2D is a...
Read MoreIn a nutshell This study evaluated whether adding vildagliptin (Galvus) to metformin (Glucophage) could improve the duration of blood glucose control for patients with newly diagnosed Type 2 Diabetes (T2D). The authors found that this treatment combination improved long-term blood glucose control for these patients. Some background...
Read MoreIn a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...
Read MoreIn a nutshell This study compared insulin degludec/liraglutide (IDegLira) to standard insulin in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that IDegLira improved patient compliance to treatment and reduced treatment-related stress compared to conventional insulin. Some background One of the main goals of treatment...
Read MoreIn a nutshell This study examined if nutritional supplements can reduce the rate of hypoglycemia in patients with Type 2 diabetes (T2D). This study concluded that these supplements helped reduce hypoglycemia and lowered mortality risk for these patients. Some background Treatment for T2D, such as insulin, can cause blood sugar levels to...
Read MoreIn a nutshell This study wanted to evaluate the safety and effectiveness of bexagliflozin in patients with type 2 diabetes (T2D). The study found that this treatment was safe and significantly improved the outcomes of these patients. Some background Bexagliflozin is a new medication for treating T2D. It is part of a larger class of...
Read MoreIn a nutshell The aim of this study was to assess the remission of type 2 diabetes (T2D) during a family doctor-led weight management programme. The main finding of the study was that after 2 years of the programme more than one-third of patients had reversed their T2D. Some background The number of people with T2D is increasing. One factor is the...
Read MoreIn a nutshell The aim of this study was to investigate the effect of SGLT2 inhibitors on the prevention of heart and kidney disease in patients with type 2 diabetes (T2D). The main outcome was that SGLT2-inhibitors reduced hospitalization for heart failure and prevented the worsening of kidney disease in T2D. Some background There are many...
Read MoreIn a nutshell The aim of this study is the test the effectiveness of new drug BTI320 on blood glucose control in type 2 diabetes (T2D). The main outcome to be measured will be a change in blood glucose 2 hours after meals. This study is being carried out in the United States. The details The number of patients with T2D is constantly on the rise....
Read MoreIn a nutshell The aim of this study was to evaluate how safe and effective ertugliflozin (Steglatro) is in patients with type 2 diabetes (T2D) that is not controlled well with metformin (Glucophage). The study found that ertugliflozin is safe and improved blood glucose control, body weight, and blood pressure in these patients. Some background...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of adding sitagliptin (Januvia) to treatment with pre-mixed insulin in patients with poorly controlled Type 2 diabetes (T2D). This study concluded that sitagliptin was well-tolerated and significantly improved glycemic (blood sugar) control in these patients. Some background As...
Read MoreIn a nutshell This study evaluated the risk of genital infections in patients with Type 2 diabetes (T2D) treated with SGLT2 (sodium-glucose cotransporter 2) inhibitors. This study concluded that this therapy was associated with a 3-fold higher risk of genital infections in these patients. Some background SGLT2 inhibitors help the kidneys remove...
Read More
